Cytomegalovirus latency and reactivation: recent insights into an age old problem

Reviews in Medical Virology

Volumn , Issue , 2016, Pages 75-89

  Dupont, Liane ^a   Reeves, Matthew B ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

UNTRANSLATED RNA; VIRAL PROTEIN;

BONE MARROW CELL; CELL DIFFERENTIATION; CELL LINEAGE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; EPIGENETICS; GENE EXPRESSION; HUMAN; LATENT VIRUS INFECTION; MORBIDITY; MYELOID PROGENITOR CELL; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; REVIEW; TRANSCRIPTION REGULATION; VIRUS CELL INTERACTION; VIRUS GENE; VIRUS LATENCY; VIRUS REACTIVATION;

EID: 84987819728     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.1862     Document Type: Review

References (121)

1. Griffiths P, Baraniak I, Reeves M. The pathogenesis of human cytomegalovirus. Journal of Pathology 2015; 235: 288–297.
2. Jackson SE, Mason GM, Wills MR. Human cytomegalovirus immunity and immune evasion. Virus Research 2011; 157(2): 151–160.
3. Legendre C, Pascual M. Improving outcomes for solid-organ transplant recipients at risk from cytomegalovirus infection: late-onset disease and indirect consequences. Clinical Infectious Diseases 2008; 46(5): 732–740.
4. Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Reviews in Medical Virology 2007; 17(4): 253–276.
5. Boeckh M, Nichols WG. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 2004; 103(6): 2003–2008.
6. Lanzieri TM, Dollard SC, Bialek SR, Grosse SD. Systematic review of the birth prevalence of congenital cytomegalovirus infection in developing countries. International Journal of Infectious Diseases 2013; 22: 44–48.
7. Chen HS, Lu F, Lieberman PM. Epigenetic regulation of EBV and KSHV latency. Current Opinion in Virology 2013; 3(3): 251–259.
8. Knipe DM, Cliffe A. Chromatin control of herpes simplex virus lytic and latent infection. Nature Reviews Microbiology 2008; 6(3): 211–221.
9. Reeves M, Sinclair J. Aspects of human cytomegalovirus latency and reactivation. Current Topics in Microbiology and Immunology 2008; 325: 297–313.
10. Liu XF, Wang X, Yan S, Zhang Z, Abecassis M, Hummel M. Epigenetic control of cytomegalovirus latency and reactivation. Viruses 2013; 5(5): 1325–1345.
11. Reeves MB, Coleman H, Chadderton J, Goddard M, Sissons JG, Sinclair JH. Vascular endothelial and smooth muscle cells are unlikely to be major sites of latency of human cytomegalovirus in vivo. Journal of General Virology 2004; 85(Pt 11): 3337–3341.
12. Fish KN, Soderberg-Naucler C, Mills LK, Stenglein S, Nelson JA. Human cytomegalovirus persistently infects aortic endothelial cells. Journal of Virology 1998; 72(7): 5661–5668.
13. Pollock JL, Presti RM, Paetzold S, Virgin HW 4th. Latent murine cytomegalovirus infection in macrophages. Virology 1997; 227(1): 168–179.
14. Daley-Bauer LP, Roback LJ, Wynn GM, Mocarski ES. Cytomegalovirus hijacks CX3CR1(hi) patrolling monocytes as immune-privileged vehicles for dissemination in mice. Cell Host & Microbe 2014; 15(3): 351–362.
15. Odeberg J, Wolmer N, Falci S, Westgren M, Seiger Å, Söderberg-Nauclér C. Human cytomegalovirus inhibits neuronal differentiation and induces apoptosis in human neural precursor cells. Journal of Virology 2006; 80(18): 8929–8939.
16. D'Aiuto L, Di Maio R, Heath B, et al. Human induced pluripotent stem cell-derived models to investigate human cytomegalovirus infection in neural cells. PloS One 2012; 7(11): e49700.
17. Belzile JP, Stark TJ, Yeo GW, Spector DH. Human cytomegalovirus infection of human embryonic stem cell-derived primitive neural stem cells is restricted at several steps but leads to the persistence of viral DNA. Journal of Virology 2014; 88(8): 4021–4039.
18. Luo MH, Schwartz PH, Fortunato EA. Neonatal neural progenitor cells and their neuronal and glial cell derivatives are fully permissive for human cytomegalovirus infection. Journal of Virology 2008; 82(20): 9994–10007.
19. Taylor-Wiedeman J, Sissons P, Sinclair J. Induction of endogenous human cytomegalovirus gene expression after differentiation of monocytes from healthy carriers. Journal of Virology 1994; 68(3): 1597–1604.
20. Yee LF, Lin PL, Stinski MF. Ectopic expression of HCMV IE72 and IE86 proteins is sufficient to induce early gene expression but not production of infectious virus in undifferentiated promonocytic THP-1 cells. Virology 2007; 363(1): 174–188.
21. Umbach JL, Kramer MF, Jurak I, Karnowski HW, Coen DM, Cullen BR. MicroRNAs expressed by herpes simplex virus 1 during latent infection regulate viral mRNAs. Nature 2008; 454(7205): 780–783.
22. Flores O, Nakayama S, Whisnant AW, Javanbakht H, Cullen BR, Bloom DC. Mutational inactivation of herpes simplex virus 1 microRNAs identifies viral mRNA targets and reveals phenotypic effects in culture. Journal of Virology 2013; 87(12): 6589–6603.
23. Perng GC, Jones C, Ciacci-Zanella J, et al. Virus-induced neuronal apoptosis blocked by the herpes simplex virus latency-associated transcript. Science 2000; 287(5457): 1500–1503.
24. Pfeffer S, Zavolan M, Grässer FA, et al. Identification of virus-encoded microRNAs. Science 2004; 304(5671): 734–736.
25. Cai X, Lu S, Zhang Z, Gonzalez CM, Damania B, Cullen BR. Kaposi's sarcoma-associated herpesvirus expresses an array of viral microRNAs in latently infected cells. Proceedings of the National Academy of Sciences of the United States of America 2005; 102(15): 5570–5575.
26. Miyashita EM, Yang B, Lam KM, Crawford DH, Thorley-Lawson DA. A novel form of Epstein–Barr virus latency in normal B cells in vivo. Cell 1995; 80(4): 593–601.
27. Babcock GJ, Hochberg D, Thorley-Lawson AD. The expression pattern of Epstein–Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 2000; 13(4): 497–506.
28. Kondo K, Kaneshima H, Mocarski ES. Human cytomegalovirus latent infection of granulocyte-macrophage progenitors. Proceedings of the National Academy of Sciences of the United States of America 1994; 91(25): 11879–11883.
29. Jenkins C, Abendroth A, Slobedman B. A novel viral transcript with homology to human interleukin-10 is expressed during latent human cytomegalovirus infection. Journal of Virology 2004; 78(3): 1440–1447.
30. Beisser PS, Laurent L, Virelizier JL, Michelson S. Human cytomegalovirus chemokine receptor gene US28 is transcribed in latently infected THP-1 monocytes. Journal of Virology 2001; 75(13): 5949–5957.
31. Goodrum FD, Jordan CT, High K, Shenk T. Human cytomegalovirus gene expression during infection of primary hematopoietic progenitor cells: a model for latency. Proceedings of the National Academy of Sciences of the United States of America 2002; 99(25): 16255–16260.
32. Reeves MB, Sinclair JH. Analysis of latent viral gene expression in natural and experimental latency models of human cytomegalovirus and its correlation with histone modifications at a latent promoter. Journal of General Virology 2010; 91(Pt 3): 599–604.
33. Rossetto CC, Tarrant-Elorza M, Pari GS. Cis and trans acting factors involved in human cytomegalovirus experimental and natural latent infection of CD14 (+) monocytes and CD34 (+) cells. PLoS Pathogen 2013; 9(5): e1003366.
34. Bego M, Maciejewski J, Khaiboullina S, Pari G, St Jeor S. Characterization of an antisense transcript spanning the UL81-82 locus of human cytomegalovirus. Journal of Virology 2005; 79(17): 11022–11034.
35. Goodrum F, Reeves M, Sinclair J, High K, Shenk T. Human cytomegalovirus sequences expressed in latently infected individuals promote a latent infection in vitro. Blood 2007; 110(3): 937–945.
36. Kondo K, Xu J, Mocarski ES. Human cytomegalovirus latent gene expression in granulocyte-macrophage progenitors in culture and in seropositive individuals. Proceedings of the National Academy of Sciences of the United States of America 1996; 93(20): 11137–11142.
37. Poole E, Walther A, Raven K, Benedict CA, Mason GM, Sinclair J. The myeloid transcription factor GATA-2 regulates the viral UL144 gene during human cytomegalovirus latency in an isolate-specific manner. Journal of Virology 2013; 87(8): 4261–4271.
38. Reeves MB, Davies AA, McSharry BP, Wilkinson GW, Sinclair JH. Complex I binding by a virally encoded RNA regulates mitochondria-induced cell death. Science 2007; 316(5829): 1345–1348.
39. Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature 2011; 469(7330): 343–349.
40. Reeves MB, MacAry PA, Lehner PJ, Sissons JG, Sinclair JH. Latency, chromatin remodeling, and reactivation of human cytomegalovirus in the dendritic cells of healthy carriers. Proceedings of the National Academy of Sciences of the United States of America 2005; 102(11): 4140–4145.
41. Saffert RT, Penkert RR, Kalejta RF. Cellular and viral control over the initial events of human cytomegalovirus experimental latency in CD34+ cells. Journal of Virology 2010; 84(11): 5594–5604.
42. Cliffe AR, Coen DM, Knipe DM. Kinetics of facultative heterochromatin and polycomb group protein association with the herpes simplex viral genome during establishment of latent infection. MBio Journal 2013; 4(1). pii: e00590–12.
43. Rossetto CC, Pari G. KSHV PAN RNA associates with demethylases UTX and JMJD3 to activate lytic replication through a physical interaction with the virus genome. PLoS Pathogen 2012; 8(5): e1002680.
44. Grey F. Role of microRNAs in herpesvirus latency and persistence. Journal of General Virology 2015; 96(Pt 4): 739–751.
45. Meshesha MK, Bentwich Z, Solomon SA, Avni YS. In vivo expression of human cytomegalovirus (HCMV) microRNAs during latency. Gene 2015. doi: 10.1016/j.gene.2015.08.040. [Epub ahead of print]
46. Grey F, Meyers H, White EA, Spector DH, Nelson J. A human cytomegalovirus-encoded microRNA regulates expression of multiple viral genes involved in replication. PLoS Pathogen 2007; 3(11): e163.
47. Murphy E, Vanícek J, Robins H, Shenk T, Levine AJ. Suppression of immediate-early viral gene expression by herpesvirus-coded microRNAs: implications for latency. Proceedings of the National Academy of Sciences of the United States of America 2008; 105(14): 5453–5458.
48. Kew VG, Yuan J, Meier J, Reeves MB. Mitogen and stress activated kinases act co-operatively with CREB during the induction of human cytomegalovirus immediate-early gene expression from latency. PLoS Pathogen 2014; 10(6): e1004195.
49. O'Connor CM, Murphy EA. A myeloid progenitor cell line capable of supporting human cytomegalovirus latency and reactivation, resulting in infectious progeny. Journal of Virology 2012; 86(18): 9854–9865.
50. O'Connor CM, Vanicek J, Murphy EA. Host microRNA regulation of human cytomegalovirus immediate early protein translation promotes viral latency. Journal of Virology 2014; 88(10): 5524–5532.
51. Poole E, McGregor Dallas SR, Colston J, Joseph RS, Sinclair J. Virally induced changes in cellular microRNAs maintain latency of human cytomegalovirus in CD34(+) progenitors. Journal of General Virology 2011; 92(Pt 7): 1539–1549.
52. Pan D, Flores O, Umbach JL, et al. A neuron-specific host microRNA targets herpes simplex virus-1 ICP0 expression and promotes latency. Cell Host & Microbe 2014; 15(4): 446–456.
53. Bodaghi B, Jones TR, Zipeto D, et al. Chemokine sequestration by viral chemoreceptors as a novel viral escape strategy: withdrawal of chemokines from the environment of cytomegalovirus-infected cells. Journal of Experimental Medicine 1998; 188(5): 855–866.
54. Tan JC, Avdic S, Cao JZ, et al. Inhibition of 2′,5′-oligoadenylate synthetase expression and function by the human cytomegalovirus ORF94 gene product. Journal of Virology 2011; 85(11): 5696–5700.
55. Poole E, King CA, Sinclair JH, Alcami A. The UL144 gene product of human cytomegalovirus activates NFkappaB via a TRAF6-dependent mechanism. EMBO Journal 2006; 25(18): 4390–4399.
56. Montag C, Wagner JA, Gruska I, Vetter B, Wiebusch L, Hagemeier C. The latency-associated UL138 gene product of human cytomegalovirus sensitizes cells to tumor necrosis factor alpha (TNF-alpha) signaling by upregulating TNF-alpha receptor 1 cell surface expression. Journal of Virology 2011; 85(21): 11409–11421.
57. Le VT, Trilling M, Hengel H. The cytomegaloviral protein pUL138 acts as potentiator of tumor necrosis factor (TNF) receptor 1 surface density to enhance ULb′-encoded modulation of TNF-alpha signaling. Journal of Virology 2011; 85(24): 13260–13270.
58. Slobedman B, Cao JZ, Avdic S, et al. Human cytomegalovirus latent infection and associated viral gene expression. Future Microbiology 2010; 5(6): 883–900.
59. Mason GM, Poole E, Sissons JG, Wills MR, Sinclair JH. Human cytomegalovirus latency alters the cellular secretome, inducing cluster of differentiation (CD)4+ T-cell migration and suppression of effector function. Proceedings of the National Academy of Sciences of the United States of America 2012; 109(36): 14538–14543.
60. Avdic S, Cao JZ, Cheung AK, Abendroth A, Slobedman B. Viral interleukin-10 expressed by human cytomegalovirus during the latent phase of infection modulates latently infected myeloid cell differentiation. Journal of Virology 2011; 85(14): 7465–7471.
61. Avdic S, Cao JZ, McSharry BP, et al. Human cytomegalovirus interleukin-10 polarizes monocytes toward a deactivated M2c phenotype to repress host immune responses. Journal of Virology 2013; 87(18): 10273–10282.
62. Poole E, Avdic S, Hodkinson J, et al. Latency-associated viral interleukin-10 (IL-10) encoded by human cytomegalovirus modulates cellular IL-10 and CCL8 Secretion during latent infection through changes in the cellular microRNA hsa-miR-92a. Journal of Virology 2014; 88(24): 13947–13955.
63. Poole E, Lau J, Sinclair J. Latent infection of myeloid progenitors by human cytomegalovirus protects cells from FAS-mediated apoptosis through the cellular IL-10/PEA15 pathway. Journal of General Virology 2015; 96(8): 2355–2359.
64. Hahn G, Jores R, Mocarski ES. Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cells. Proceedings of the National Academy of Sciences of the United States of America 1998; 95(7): 3937–3942.
65. Tarrant-Elorza M, Rossetto CC, Pari GS. Maintenance and replication of the human cytomegalovirus genome during latency. Cell Host & Microbe 2014; 16(1): 43–54.
66. Cotter MA 2nd, Robertson ES. The latency-associated nuclear antigen tethers the Kaposi's sarcoma-associated herpesvirus genome to host chromosomes in body cavity-based lymphoma cells. Virology 1999; 264(2): 254–264.
67. Petrucelli A, Rak M, Grainger L, Goodrum F. Characterization of a novel Golgi apparatus-localized latency determinant encoded by human cytomegalovirus. Journal of Virology 2009; 83(11): 5615–5629.
68. Hargett D, Shenk TE. Experimental human cytomegalovirus latency in CD14+ monocytes. Proceedings of the National Academy of Sciences of the United States of America 2010; 107(46): 20039–20044.
69. Slobedman B, Mocarski ES. Quantitative analysis of latent human cytomegalovirus. Journal of Virology 1999; 73(6): 4806–4812.
70. Lee MA, Diamond ME, Yates JL. Genetic evidence that EBNA-1 is needed for efficient, stable latent infection by Epstein–Barr virus. Journal of Virology 1999; 73(4): 2974–2982.
71. Roughan JE, Torgbor C, Thorley-Lawson DA. Germinal center B cells latently infected with Epstein–Barr virus proliferate extensively but do not increase in number. Journal of Virology 2010; 84(2): 1158–1168.
72. Reinhardt J, Smith GB, Himmelheber CT, Azizkhan-Clifford J, Mocarski ES. The carboxyl-terminal region of human cytomegalovirus IE1491aa contains an acidic domain that plays a regulatory role and a chromatin-tethering domain that is dispensable during viral replication. Journal of Virology 2005; 79(1): 225–233.
73. Kern F, Surel IP, Faulhaber N, et al. Target structures of the CD8(+)-T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited. Journal of Virology 1999; 73(10): 8179–8184.
74. Borysiewicz LK, Hickling JK, Graham S, et al. Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses. Journal of Experimental Medicine 1988; 168(3): 919–931.
75. Jackson SE, Mason GM, Okecha G, Sissons JG, Wills MR. Diverse specificities, phenotypes, and antiviral activities of cytomegalovirus-specific CD8+ T cells. Journal of Virology 2014; 88(18): 10894–10908.
76. Mason G, Jackson SE, Okecha G, et al. Human cytomegalovirus latency-associated proteins elicit immune-suppressive IL-10 producing CD4+ T cells. PLoS Pathogen 2013; 9(10): e1003635.
77. Reeves MB, Sinclair JH. Circulating dendritic cells isolated from healthy seropositive donors are sites of human cytomegalovirus reactivation in vivo. Journal of Virology 2013; 87(19): 10660–10667.
78. Soderberg-Naucler C, Fish KN, Nelson JA. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 1997; 91(1): 119–126.
79. Zhuravskaya T, Maciejewski JP, Netski DM, Bruening E, Mackintosh FR, St Jeor S. Spread of human cytomegalovirus (HCMV) after infection of human hematopoietic progenitor cells: model of HCMV latency. Blood 1997; 90(6): 2482–2491.
80. Poole E, Juss JK, Krishna B, Herre J, Chilvers ER, Sinclair J. Alveolar macrophages isolated directly from human cytomegalovirus (HCMV)-seropositive individuals are sites of HCMV reactivation in vivo. Journal of Infectious Diseases 2015; 211(12): 1936–1942.
81. Guenther MG, Levine SS, Boyer LA, Jaenisch R, Young RA. A chromatin landmark and transcription initiation at most promoters in human cells. Cell 2007; 130(1): 77–88.
82. Meier JL, Stinski MF. Regulation of human cytomegalovirus immediate-early gene expression. Intervirology 1996; 39(5–6): 331–342.
83. Ioudinkova E, Arcangeletti MC, Rynditch A, et al. Control of human cytomegalovirus gene expression by differential histone modifications during lytic and latent infection of a monocytic cell line. Gene 2006; 384: 120–128.
84. Reeves MB. Chromatin-mediated regulation of cytomegalovirus gene expression. Virus Research 2011; 157(2): 134–143.
85. Prösch S, Wuttke R, Krüger DH, Volk HD. NF-kappaB—a potential therapeutic target for inhibition of human cytomegalovirus (re)activation? Biological Chemistry 2002; 383(10): 1601–1609.
86. Kline JN, Hunninghake GM, He B, Monick MM, Hunninghake GW. Synergistic activation of the human cytomegalovirus major immediate early promoter by prostaglandin E2 and cytokines. Experimental Lung Research 1998; 24(1): 3–14.
87. Reeves MB, Compton T. Inhibition of inflammatory interleukin-6 activity via extracellular signal-regulated kinase-mitogen-activated protein kinase signaling antagonizes human cytomegalovirus reactivation from dendritic cells. Journal of Virology 2011; 85(23): 12750–12758.
88. Humar A, St Louis P, Mazzulli T, et al. Elevated serum cytokines are associated with cytomegalovirus infection and disease in bone marrow transplant recipients. Journal of Infectious Diseases 1999; 179(2): 484–488.
89. Tong CY, Bakran A, Williams H, Cuevas LE, Peiris JS, Hart CA. Association of tumour necrosis factor alpha and interleukin 6 levels with cytomegalovirus DNA detection and disease after renal transplantation. Journal of Medical Virology 2001; 64(1): 29–34.
90. Huang MM, Kew VG, Jestice K, Wills MR, Reeves MB. Efficient human cytomegalovirus reactivation is maturation dependent in the Langerhans dendritic cell lineage and can be studied using a CD14+ experimental latency model. Journal of Virology 2012; 86(16): 8507–8515.
91. Saccani S, Pantano S, Natoli G. p38-dependent marking of inflammatory genes for increased NF-kappa B recruitment. Nature Immunology 2002; 3(1): 69–75.
92. Keller MJ, Wu AW, Andrews JI, McGonagill PW, Tibesar EE, Meier JL. Reversal of human cytomegalovirus major immediate-early enhancer/promoter silencing in quiescently infected cells via the cyclic AMP signaling pathway. Journal of Virology 2007; 81(12): 6669–6681.
93. Yuan J, Liu X, Wu AW, et al. Breaking human cytomegalovirus major immediate-early gene silence by vasoactive intestinal peptide stimulation of the protein kinase A-CREB-TORC2 signaling cascade in human pluripotent embryonal NTera2 cells. Journal of Virology 2009; 83(13): 6391–6403.
94. Prösch S, Döcke WD, Reinke P, Volk HD, Krüger DH. Human cytomegalovirus reactivation in bone-marrow-derived granulocyte/monocyte progenitor cells and mature monocytes. Intervirology 1999; 42(5–6): 308–313.
95. Zhang X, Odom DT, Koo SH, et al. Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. Proceedings of the National Academy of Sciences of the United States of America 2005; 102(12): 4459–4464.
96. Smale ST. Selective transcription in response to an inflammatory stimulus. Cell 2010; 140(6): 833–844.
97. Natoli G. Maintaining cell identity through global control of genomic organization. Immunity 2010; 33(1): 12–24.
98. Agalioti T, Lomvardas S, Parekh B, Yie J, Maniatis T, Thanos D. Ordered recruitment of chromatin modifying and general transcription factors to the IFN-beta promoter. Cell 2000; 103(4): 667–678.
99. Badeaux AI, Shi Y. Emerging roles for chromatin as a signal integration and storage platform. Nature Reviews Molecular Cell Biology 2013; 14(4): 211–224.
100. Shimada M, Nakadai T, Fukuda A, Hisatake K. cAMP-response element-binding protein (CREB) controls MSK1-mediated phosphorylation of histone H3 at the c-fos promoter in vitro. Journal of Biological Chemistry 2010; 285(13): 9390–9401.
101. Fischle W, Tseng BS, Dormann HL, et al. Regulation of HP1-chromatin binding by histone H3 methylation and phosphorylation. Nature 2005; 438(7071): 1116–1122.
102. Loomis RJ, Naoe Y, Parker JB, et al. Chromatin binding of SRp20 and ASF/SF2 and dissociation from mitotic chromosomes is modulated by histone H3 serine 10 phosphorylation. Molecular Cell 2009; 33(4): 450–461.
103. Macdonald N, Welburn JP, Noble ME, et al. Molecular basis for the recognition of phosphorylated and phosphoacetylated histone h3 by 14-3-3. Molecular Cell 2005; 20(2): 199–211.
104. Zippo A, Serafini R, Rocchigiani M, Pennacchini S, Krepelova A, Oliviero S. Histone crosstalk between H3S10ph and H4K16ac generates a histone code that mediates transcription elongation. Cell 2009; 138(6): 1122–1136.
105. Abraham CG, Kulesza CA. Polycomb repressive complex 2 silences human cytomegalovirus transcription in quiescent infection models. Journal of Virology 2013; 87(24): 13193–13205.
106. Lienert F, Mohn F, Tiwari VK, et al. Genomic prevalence of heterochromatic H3K9me2 and transcription do not discriminate pluripotent from terminally differentiated cells. PLoS Genetics 2011; 7(6): e1002090.
107. Fischle W, Wang Y, Jacobs SA, Kim Y, Allis CD, Khorasanizadeh S. Molecular basis for the discrimination of repressive methyl-lysine marks in histone H3 by Polycomb and HP1 chromodomains. Genes and Development 2003; 17(15): 1870–1881.
108. Drobic B, Pérez-Cadahía B, Yu J, Kung SK, Davie JR. Promoter chromatin remodeling of immediate-early genes is mediated through H3 phosphorylation at either serine 28 or 10 by the MSK1 multi-protein complex. Nucleic Acids Research 2010; 38(10): 3196–3208.
109. Boros J, Arnoult N, Stroobant V, Collet JF, Decottignies A. Polycomb repressive complex 2 and H3K27me3 cooperate with H3K9 methylation to maintain heterochromatin protein 1alpha at chromatin. Molecular and Cellular Biology 2014; 34(19): 3662–3674.
110. Sawicka A, Seiser C. Sensing core histone phosphorylation—a matter of perfect timing. Biochimica et Biophysica Acta 2014; 1839(8): 711–718.
111. Reeves M, Murphy J, Greaves R, Fairley J, Brehm A, Sinclair J. Autorepression of the human cytomegalovirus major immediate-early promoter/enhancer at late times of infection is mediated by the recruitment of chromatin remodeling enzymes by IE86. Journal of Virology 2006; 80(20): 9998–10009.
112. Zalckvar E, Paulus C, Tillo D, et al. Nucleosome maps of the human cytomegalovirus genome reveal a temporal switch in chromatin organization linked to a major IE protein. Proceedings of the National Academy of Sciences of the United States of America 2013; 110(32): 13126–13131.
113. Nevels M, Paulus C, Shenk T. Human cytomegalovirus immediate-early 1 protein facilitates viral replication by antagonizing histone deacetylation. Proceedings of the National Academy of Sciences of the United States of America 2004; 101(49): 17234–17239.
114. Nitzsche A, Paulus C, Nevels M. Temporal dynamics of cytomegalovirus chromatin assembly in productively infected human cells. Journal of Virology 2008; 82(22): 11167–11180.
115. Stasevich TJ, Hayashi-Takanaka Y, Sato Y, et al. Regulation of RNA polymerase II activation by histone acetylation in single living cells. Nature 2014; 516(7530): 272–275.
116. Dağ F, Dölken L, Holzki J, et al. Reversible silencing of cytomegalovirus genomes by type I interferon governs virus latency. PLoS Pathogen 2014; 10(2): e1003962.
117. Marshall EE, Geballe AP. Multifaceted evasion of the interferon response by cytomegalovirus. Journal of Interferon & Cytokine Research 2009; 29(9): 609–619.
118. Trilling M, Le VT, Hengel H. Interplay between CMVs and interferon signaling: implications for pathogenesis and therapeutic intervention. Future Microbiology 2012; 7(11): 1269–1282.
119. Noriega VM, Haye KK, Kraus TA, et al. Human cytomegalovirus modulates monocyte-mediated innate immune responses during short-term experimental latency in vitro. Journal of Virology 2014; 88(16): 9391–9405.
120. Umashankar M, Petrucelli A, Cicchini L, et al. A novel human cytomegalovirus locus modulates cell type-specific outcomes of infection. PLoS Pathogen 2012; 7(12): e1002444.
121. Weekes MP, Tan SY, Poole E, et al. Latency-associated degradation of the MRP1 drug transporter during latent human cytomegalovirus infection. Science 2013; 340(6129): 199–202.